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Background: For clinicians, a practical bedside tool for severity assessment and prognosis of
patients with Clostridium difﬁcile infection is a highly desirable unmet medical need.
Setting: Two general teaching hospitals in northeast Mexico.
Population: Adult patients with C. difﬁcile infection.
Methods: Prospective observational study.
Results: Patients included had a median of 48 years of age, 54% of male gender and an average
of  24.3 days length of hospital stay. Third generation cephalosporins were the antibiotics
most  commonly used prior to C. difﬁcile infection diagnosis. Patients diagnosed with C. difﬁcile
infection had a median ATLAS score of 4 and 56.7% of the subjects had a score between 4
and  7 points. Patients with a score of 8 through 10 points had 100% mortality.
Conclusion: The ATLAS score is a potentially useful tool for the routine evaluation of patients
at  the time of C. difﬁcile infection diagnosis. At 30 days post-diagnosis, patients with a score
of  ≤3 points had 100% survival while all of those with scores ≥8 died. Patients with scores
between 4 and 7 points had a greater probability of colectomy with an overall cure rate of
70.1%.
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and another with a score of 7 all of whom survived. In addition,
no deaths or colectomies occurred among the patients having
an ATLAS score of 2 points or less.
Table 2 – Characteristics and outcome of the study
population of CDI patients.
Demographic characteristics n = 102
Mean age 49.79 (15–97)
Male gender 55 (53.92%)
Risk factors
Average BMI 25.69
Total LOS (days) 24.38
LOS before CDI diagnosis 11.89
LOS after CDI diagnosis 12.72
Mean number of antibiotics use before CDI 2.35
Average antibiotic days before CDI 14.61
Postsurgical diagnosis 46 (45.9%)
Clinical characteristics
Average number of bowel movements 5.59
Days with diarrhea before diagnosis of CDI 5.38
Average leukocyte count 13,897400  b r a z j i n f e c t d 
Introduction
Clostridium difﬁcile infection (CDI) is a serious threat in the
hospital setting and it is now one of the leading causes
of healthcare-associated infection.1,2 Serious complications
such as sepsis, toxic megacolon, need for colectomy, and death
are associated with CDI especially in those patients infected
by hypervirulent strains.3
The need of a proper instrument for severity assessment
has been previously studied with various results.4–6 For cli-
nicians, a practical bedside tool for severity assessment and
prognosis is a highly desirable unmet medical need. One of the
most practical bedside severity scoring systems is the ATLAS
system that has recently been validated7 based upon two
large clinical trials comparing vancomycin and ﬁdaxomicin
(Table 1). We  sought to apply the ATLAS score in two Mexican
teaching hospitals and compare some of our ﬁndings to the
published data.
Methods
This prospective study was performed from November 2011
to March 2014. The study was carried out in two teaching
hospitals from the northeastern region of Mexico: the Uni-
versity Hospital “Dr. José Eleuterio González” tertiary care
hospital with 450 beds in Monterrey and Hospital Christus
Muguerza Alta Especialidad a private teaching hospital with
200 beds. Patients were included in the study if they were hos-
pitalized for more  than 48 h and had more  than three bowel
movements in the previous 24 h (Bristol scale 6–7), and no
other cause of diarrhea plus a positive C. difﬁcile toxin assay
(Immunocard toxin AB, Meridian Bioscience Inc.); and/or a
colonoscopy showing pseudomembranous colitis. All cases
had to have a positive stool culture for toxigenic C. difﬁcile.
Clinical cure was deﬁned as the absence of diarrhea or inﬂam-
matory response at the end of treatment and no recurrence
28 days after the end of treatment. For comparison of dichoto-
mous variables we  applied Fishers exact test or Chi-Square
test. A p-value of ≤0.05 was considered statistically signiﬁ-
cant.
ResultsA total of 102 patients were included with a median of 48 years
of age and a slight predominance of males (54%). They had an
Table 1 – The ATLAS scoring system and the number of
points per characteristic.
Points
0 1 2
Age (years) ≤60 60–70 >70
Temperature (◦C) ≤37.6 37.6–38.5 >38.6
Leucocytes (K/mL) ≤16 16–25 >25
Albumin (g/mL) ≥3.5 2.6–3.4 <2.5
Systemic antibiotics Yes – No 1 5;1  9(4):399–402
average length of hospital stay (LOS) of 24.3 days, 14.6 days of
antibiotic therapy, and 5.3 days of diarrhea prior to CDI diagno-
sis. Third generation cephalosporins were the antibiotics most
commonly used prior to CDI diagnosis (47.0%) followed by ﬂu-
oroquinolones (33.3%) and clindamycin (23.5%). There were
3.9% (4/102) total colectomies and 30-day all-cause mortality
was 17.6% (18/102) (Table 2).
Metronidazole was the treatment for 58/102 patients
(56.8%), oral vancomycin in 7/102 (6.8%), and a combination
of metronidazole PO/IV and vancomycin PO in 37/102 patients
(36.2%). Mortality was statistically different between patients
with a serum albumin of ≤2.5 g/dL compared with those with
higher albumin levels [18 (40%) vs. 4 (7.0%) p < 0.0001].
The day on which the patients were diagnosed with CDI,
the distribution of ATLAS scores among this cohort can be seen
in Table 2. All four patients with a score of eight or greater died
during the 30 days after the diagnosis of CDI: three of them
as a result of septic complications of CDI and the remaining
patient because of cancer related complications. There were
four colectomies performed as a therapeutic measure for CDI;
two patients with a score of 5 points each, one with a score of 6Fever 55 (53.9%)
Outcome
≤28 day mortality 18 (17.6%)
>28 day mortality 5 (4.9%)
Median ATLAS score 4
Colectomy 4 (3.9%)
Prior antibiotics used
Third generation cephalosporins 48 (47.05%)
Fluoroquinolones 34 (33.3%)
Carbapenems 26 (25.4%)
Clindamycin 24 (23.52%)
Antibiotics used for the treatment of CDI
Metronidazole 58 (56.86%)
Vancomycin 7 (6.86%)
Metronidazole + vancomycin 37 (36.27%)
CDI, Clostridium difﬁcile infection; LOS, length of stay.
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Table 3 – Comparison between colectomy, 28-day mortality and cure rates using the ATLAS score in 2 different groups.
ATLAS score No. patients Colectomy (n) Mortality rate (n) Cure rate (n = 102) Miller et al.a (n = 452) pb
0 5 0 0 (0) 100 (5/5) 95.7 (66/69) 0.63
1 5 0 0 (0) 100 (5/5) 93.3 (83/89) 0.55
2 11 0 0 (0) 100 (11/11) 92.7 (63/68) 0.79
3 19 0 5.2 (1) 94.7 (18/19) 89.5 (77/86) 0.54
4 22 0 22.7 (5) 77.2 (17/22) 81.1 (43/53) 0.95
5 13 15.3 (2) 30.7 (4) 69.2 (9/13) 76.1 (35/46) 0.89
6 15 6.6 (1) 53.3 (8) 46.6 (7/15) 85.7 (18/21) 0.03
7 8 12.5 (1) 12.5 (1) 87.5 (1/8) 50.0 (4/8) 0.28
8 2 0 100 (2) 0 (0/2) 55.6 (5/9) 0.52
9 1 0 100 (1) 0 (0/1) 33.3 (1/3) 0.5
10 1 0 100 (1) 0 (0/1) NA NA
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b Difference in the cure rate between the current study and Miller et
iscussion
 simple bedside scoring system for evaluating severity and
rognosis in CDI patients continues to be an important unmet
edical need. The ATLAS score is one of the simplest tools for
he prediction of cure in patients with CDI. The score was val-
dated in a large database7 that was extrapolated from two
DI studies8,9 comparing vancomycin and ﬁdaxomicin for the
reatment of CDI. In the current study we applied the ATLAS
coring system in a cohort of patients diagnosed with CDI
nd followed them prospectively. The cure rate was similar
o the previous description7 of this scoring system with the
xception of the group with a score of 6 points, in which
ur group had a lower cure rate (Table 3). In this prospec-
ive observational study, we  did not intervene or alter the
reatments since those variables were decided by the treat-
ng physician. Although the study did not interfere with the
reatment decision, the majority of patients with severe dis-
ase received vancomycin as suggested by current guidelines
nd other studies.10,11 None of the patients were treated with
daxomicin since this medication was not available in Mex-
co at the time of the study. Several severity scores have been
pplied in patients with CDI with sensitivities ranging from
3.2% to 84.2%, and speciﬁcities ranging from 59.4% to 93.9%.12
he scoring system used in our study was originally applied
s a predictor of cure but in the current study we additionally
orrelated the score with the need for colectomy and mortality
ate, thus enhancing its utility.
The decision for performing a total colectomy was evalu-
ted by the treating medical staff and was not controlled by our
tudy investigators. In the current study the four patients with
n ATLAS score of ≥8 died without a colectomy. This could be
 reﬂection of their severe clinical condition and the reluc-
ance to refer them for surgery, or a direct consequence of the
resence of fulminant colitis and/or sepsis due to the CDI.
onclusionur study evaluated the ATLAS score in a teaching hospi-
al scenario ﬁnding it a useful tool for routine evaluation of
atients with CDI. Those patients with a score of ≤3 points had
n excellent prognosis while those who  had scores between 4and 7 points had a greater probability of having a colectomy.
Patients with scores ≥8 had 100% mortality, but it is unclear if
that was due to the severity of their colitis or because an early
enough colectomy was not performed.
In summary, the ATLAS score at the time of CDI diagnosis
in our patient population can be used to predict survival and
the need for consideration of colectomy. Additionally, it can
aid clinicians in choosing which patients to monitor closely
and to intervene in order to prevent or treat CDI-related com-
plications, morbidity and mortality.
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